Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CharactHer: A Study of the Molecular and Cytogenetic Characteristics of HER2-positive Breast Cancers to Predict Durable Complete Response After Chemotherapy and Trastuzumab

NCT01722890 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT01722890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01722890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CharactHer: A Study of the Molecular and Cytogenetic Characteristics of HER2-positive Breast Cancers to Predict Durable Complete Response After Chemotherapy and Trastuzumab
Lead sponsor
Cancer Trials Ireland
Phase
Observational
Overall status
Terminated
Start date
July 31, 2012
Completion date
January 27, 2021
Enrollment
130 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer, tnm stage ii-iv breast cancer